Evidence map›Paper›PMID 36613827›Full record

ReviewInternational journal of molecular sciences2022

IL-33 and IL-37: A Possible Axis in Skin and Allergic Diseases.

Francesco Borgia, Paolo Custurone, Federica Li Pomi, Mario Vaccaro, Clara Alessandrello, Sebastiano Gangemi

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. ProbioticFrontiers in nutrition · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Francesco BorgiaDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.ORCID 0000-0003-3515-8441
Paolo CusturoneDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.ORCID 0000-0002-2142-5054
Federica Li PomiDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.ORCID 0000-0001-6760-9468
Mario VaccaroDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.ORCID 0000-0003-3787-5145
Clara AlessandrelloDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy.
Sebastiano GangemiDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin (IL)-37 and IL-33 are among the latest cytokines identified, playing a role in several inflammatory conditions, spanning from systemic conditions to tumors to localized diseases. As newly discovered interleukins, their role is still scarcely understood, but their potential role as therapeutic targets or disease activity markers suggests the need to reorganize the current data for a better interpretation. The aim of this review is to collect and organize data produced by several studies to create a complete picture. The research was conducted on the PubMed database, and the resulting articles were sorted by title, abstract, English language, and content. Several studies have been assessed, mostly related to atopic dermatitis and immunologic pathways. Collective data demonstrates a pro-inflammatory role of IL-33 and an anti-inflammatory one for IL-37, possibly related to each other in an IL-33/IL-37 axis. Although further studies are needed to assess the safety and plausibility of targeting these two interleukins for patients affected by skin conditions, the early results indicate that both IL-33 and IL-37 represent markers of disease activity.

Indexed as

Dermatitis, AtopicHypersensitivityCytokinesHumansInterleukin-33InterleukinsSkinCytokinesInterleukin-33Interleukinsallergic diseasesasthmaatopic dermatitiscontact dermatitisIL-33IL-37inflammationinterleukinpsoriasisskin

Identifiers

PMID36613827
PMCPMC9820694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.